Published in J Am Coll Surg on April 01, 1994
Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg (1996) 2.24
Sex differences and estrogen modulation of the cellular immune response after injury. Cell Immunol (2008) 1.16
Organ-specific inflammation following acute ethanol and burn injury. J Leukoc Biol (2008) 1.12
Decreased pulmonary inflammation following ethanol and burn injury in mice deficient in TLR4 but not TLR2 signaling. Alcohol Clin Exp Res (2010) 1.10
Development of a combined radiation and burn injury model. J Burn Care Res (2011) 1.07
Inflammatory response in multiple organs in a mouse model of acute alcohol intoxication and burn injury. J Burn Care Res (2011) 1.00
Decreased pulmonary inflammation after ethanol exposure and burn injury in intercellular adhesion molecule-1 knockout mice. J Burn Care Res (2010) 0.97
Anti-IL-6 antibody treatment but not IL-6 knockout improves intestinal barrier function and reduces inflammation after binge ethanol exposure and burn injury. Shock (2013) 0.93
Pulmonary inflammation after ethanol exposure and burn injury is attenuated in the absence of IL-6. Alcohol (2013) 0.92
Changes in the levels of interleukins 6, 8, and 10, tumor necrosis factor alpha, and granulocyte-colony stimulating factor in Korean burn patients: relation to burn size and postburn time. Ann Lab Med (2012) 0.89
Estrogen treatment following severe burn injury reduces brain inflammation and apoptotic signaling. J Neuroinflammation (2009) 0.87
Ethanol potentiates the acute fatty infiltration of liver caused by burn injury: prevention by insulin treatment. J Burn Care Res (2009) 0.85
Survival and cell mediated immunity after burn injury in aged mice. J Am Aging Assoc (2002) 0.82
Burn Survivors' Experience of Core Outcomes during Return to Life: a Qualitative Study. J Caring Sci (2014) 0.80
The contribution of interleukin-2 to effective wound healing. Exp Biol Med (Maywood) (2016) 0.78
Burn wounds infected with Pseudomonas aeruginosa triggers weight loss in rats. BMC Surg (2005) 0.77
Intestine immune homeostasis after alcohol and burn injury. Shock (2015) 0.77
Calcium-Sensing Receptor Gene: Regulation of Expression. Front Physiol (2016) 0.76
Lipidomic analysis enables prediction of clinical outcomes in burn patients. Sci Rep (2016) 0.75
Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol (1998) 3.05
Routine pelvic x-ray studies in awake blunt trauma patients: a sensible policy? J Trauma (1992) 1.72
The impact of substance use on mortality and morbidity from thermal injury. J Trauma (1995) 1.72
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 1.64
Thrombospondin 1 synthesis and function in wound repair. Am J Pathol (1996) 1.52
Neutrophil depletion in rats reduces burn-injury induced intestinal bacterial translocation. Crit Care Med (2000) 1.51
Thrombogenic potential of nonionic contrast media? Radiology (1990) 1.48
Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Circulation (1993) 1.42
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost (1999) 1.42
Laboratory assays for the evaluation of recombinant hirudin. Haemostasis (1991) 1.40
Myeloid commitment shifts toward monocytopoiesis after thermal injury and sepsis. Ann Surg (2001) 1.24
A burn center cost-reduction program. J Burn Care Rehabil (1997) 1.23
Isolation and characterization of human heparin. Biochemistry (1992) 1.21
Basic fibroblast growth factor mediates angiogenic activity in early surgical wounds. Surgery (1996) 1.20
Tumor necrosis factor and wound healing. Ann Surg (1990) 1.19
Strategies for success in academic surgery. Surgery (1995) 1.17
Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. J Med Chem (1990) 1.16
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood (1998) 1.12
Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein-1. Wound Repair Regen (2001) 1.10
Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost (2009) 1.09
Interferon-gamma increases mortality following cecal ligation and puncture. J Trauma (1994) 1.04
The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol (1992) 1.03
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
A biopsy of the use of the Baxter formula to resuscitate burns or do we do it like Charlie did it? J Burn Care Rehabil (2000) 1.01
Intoxication and injury. J Trauma (1992) 1.01
Mechanisms of neutropenia involving myeloid maturation arrest in burn sepsis. Ann Surg (1998) 1.01
Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol (1998) 0.99
Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats. Shock (1996) 0.98
Trauma care fellowships: current status and future survival. J Trauma (1998) 0.97
Neutrophil depletion prevents intestinal mucosal permeability alterations in burn-injured rats. Am J Physiol Regul Integr Comp Physiol (2000) 0.95
Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost (2005) 0.95
Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor. J Burn Care Rehabil (1997) 0.94
Colonic varices. Report of an unusual case diagnosed by radionuclide scanning, with review of the literature. Gastroenterology (1986) 0.94
General surgeons and the Advanced Trauma Life Support course: is it time to refocus? J Trauma (1995) 0.92
Norepinephrine modulates myelopoiesis after experimental thermal injury with sepsis. Ann Surg (2001) 0.92
Tissue factor antigen levels in various biological fluids. Blood Coagul Fibrinolysis (1995) 0.92
Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg (1990) 0.91
Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis. Arch Surg (1988) 0.91
Symptomatic biliary obstruction associated with juxtapapillary duodenal diverticulum. Dig Dis Sci (1988) 0.91
Role of neutrophils in burn-induced microvascular injury in the intestine. Shock (2000) 0.91
Antithrombin III concentrate in the acute phase of thermal injury. Burns (2000) 0.90
The beneficial effect of granulocyte colony-stimulating factor (G-CSF) in combination with gentamicin on survival after Pseudomonas burn wound infection. Surgery (1989) 0.90
The epidemiologic features of nosocomial infections in patients with trauma. Arch Surg (1991) 0.90
Decreasing the incidence of surgical wound infections. Validation of a surveillance-notification program. Arch Surg (1986) 0.90
Intestinal intubation in acute, mechanical small-bowel obstruction. Arch Surg (1982) 0.90
Sepsis following thermal injury. Compr Ther (1989) 0.90
Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis (2010) 0.89
Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sci (1995) 0.89
Outcome for older burn patients. Arch Surg (2000) 0.89
Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol (1991) 0.89
The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J Trauma (1992) 0.88
Expression of the lactate transporter MCT1 in macrophages. Shock (2000) 0.88
Splenic arteriovenous fistula. J Trauma (1987) 0.88
Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol (2000) 0.87
Tumor necrosis factor and cardiac function. J Trauma (1992) 0.87
Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem J (1999) 0.87
Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma (1992) 0.87
Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Thromb Res (2000) 0.87
Low molecular weight heparins. An objective overview. Drugs Aging (1992) 0.86
The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Burns (2001) 0.86
Recurrent hemorrhage into the pancreatic duct from a splenic artery aneurysm. Gastroenterology (1984) 0.86
The role of diagnostic laparoscopy in the management of trauma patients: a preliminary assessment. J Trauma (1993) 0.86
Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res Suppl (1991) 0.85
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res (1994) 0.85
Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol (2001) 0.85
The effect of interleukin 1 alpha on survival in a murine model of burn wound sepsis. Arch Surg (1990) 0.85
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases. Physiol Res (2014) 0.85
Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin Thromb Hemost (1996) 0.85
Chlorpromazine modulates cytokine expression in the liver and lung after burn injury and endotoxemia. J Trauma (2000) 0.85
The expression of cyclooxygenase and the production of prostaglandin E2 in neutrophils after burn injury and infection. J Burn Care Rehabil (2001) 0.84
Interleukin 1 beta improves survival following cecal ligation and puncture. J Surg Res (1992) 0.84
Effect of transfusion on oxygen transport in critically ill patients. Shock (1996) 0.84
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost (2000) 0.84
Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5-FU treatment. Exp Hematol (1990) 0.83
Systemic administration of interferon-gamma impairs wound healing. J Surg Res (1994) 0.83
The effects of burn injury and fluid resuscitation on cardiac function in vitro. J Trauma (1986) 0.83
Bone marrow stem cell and progenitor response to injury. Wound Repair Regen (2002) 0.83
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol (1999) 0.83
Low molecular weight heparins: are they different? Can J Cardiol (1998) 0.83
Multicenter trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the treatment of burn wounds. J Trauma (1999) 0.83
Is impaired wound healing caused by infection or nutritional depletion? Surgery (1987) 0.83
Burn-induced nitric oxide release in humans. J Trauma (1995) 0.83
Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res (1998) 0.82
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis (1988) 0.82
Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Thromb Res (1999) 0.82
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Blood Coagul Fibrinolysis (1991) 0.82